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Abstract
The double-blind randomized controlled trial (DBRCT) is the gold standard of medical re-
search. We show that DBRCTs fail to fully account for the efficacy of treatment if there are
interactions between treatment and behavior, for example, if a treatment is more effective
when patients change their exercise or diet. Since behavioral or placebo effects depend on
patients’ beliefs that they are receiving treatment, clinical trials with a single probability of
treatment are poorly suited to estimate the additional treatment benefit that arises from such
interactions. Here, we propose methods to identify interaction effects, and use those meth-
ods in a meta-analysis of data from blinded anti-depressant trials in which participant-level
data was available. Out of six eligible studies, which included three for the selective seroto-
nin re-uptake inhibitor paroxetine, and three for the tricyclic imipramine, three studies had a
high (>65%) probability of treatment. We found strong evidence that treatment probability
affected the behavior of trial participants, specifically the decision to drop out of a trial. In the
case of paroxetine, but not imipramine, there was an interaction between treatment and be-
havioral changes that enhanced the effectiveness of the drug. These data show that stan-
dard blind trials can fail to account for the full value added when there are interactions
between a treatment and behavior. We therefore suggest that a new trial design, two-by-
two blind trials, will better account for treatment efficacy when interaction effects may
be important.
Introduction
The expectation of treatment can change the unconscious and conscious behavior of experi-
mental participants [1–3], and may therefore affect measured treatment effects [4]. For exam-
ple, a participant who believes he or she is receiving treatment may decide to engage in a
number of lifestyle changes. He or she may unconsciously spend less time worrying about their
illness, or consciously decide to change diet, start exercising, or even socialize more. Placebo
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effects include the therapeutic effects of such (unconscious or conscious) behavior changes [5],
and negative effects, although possibly less common, are called nocebo effects [6, 7].
Blind trials produce consistent expectations of treatment between treatment and control
groups, so that the behavior of these groups is the same in aggregate. This ensures that the ef-
fects measured by a blind trial are due to the treatment, rather than purely behavioral or place-
bo effects. While blind trials successfully parcel out pure behavioral effects, they may also fail
to account for the value added of treatment when there are interaction effects between treat-
ment and changes in behavior. We show that this issue can be addressed by randomizing the
probability p of treatment in the trial.
Consider a hypothetical antidepressant that, unknown to the experimenter, works by con-
trolling social anxiety, allowing for more positive interactions in social situations and corre-
sponding reductions in feelings of depression. Thus, the drug is effective in reducing
depression among those that decide to socialize more, but has no effect on participants who do
not. The probability p of treatment in a blind trial will likely influence the participants’ behav-
ior: participants treated with probability p = 50% (1/1 odds) will expect more social anxiety
than participants treated with probability p = 75% (3/1 odds). As such, those with 1/1 odds of
treatment may not socialize at all, while those with 3/1 odds may, on average, be more likely to
attend social gatherings. As a result, a blind trial with 1/1 odds of treatment would measure no
effect, as the treatment is ineffective without changes in behavior. In contrast, a blind trial with
3/1 odds of treatment would measure an effect, as participants in that trial socialize more.
Methods
A simple formalization of this example clarifies why standard blind trials are generally not suit-
ed to account for a treatment’s value added when there are interaction effects between treat-
ment and behavior, and how better trials can be designed to account for such interaction
effects. For simplicity, we index the degree of behavioral change by a number b(p) 2 [0, 1] with
b(p) = 0 corresponding to no change, and b(p) = 1 corresponding to complete change. As ar-
gued above, the probability of treatment p is an important design parameter which affects the
behavior b(p) of participants. Note that participants need not have a precise understanding of
probabilities for this to be true. It just needs to be the case that participants feel that 3/1 odds of
treatment are greater than 1/1 odds of treatment.
The health outcome of interest Y depends both on a participant’s treatment status τ 2 {0,1},
and on a participant’s behavior b(p) as follows: for all τ 2 {0,1}, b(p) 2 [0, 1],
Yt;p ¼ a|{z}
baseline outcome
þ t ET
|ﬄﬄ{zﬄﬄ}
effect of treatment alone
þ bðpÞ  EB
|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
effect of behavior alone
þ t bðpÞ  EI
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
interaction effects
þ UY
|{z}
error term
ð1Þ
where ET is the effect of treatment alone, EB is the effect of behavior change alone, EI is the ef-
fect of interactions between treatment and behavior. Both effects ET and EI contribute to the
value added of the intervention since neither can be obtained without the treatment. In con-
trast, pure behavioral effects EB can be obtained without the treatment and do not contribute
to the value added. (See Technical Appendix 1 for a general derivation of Eq (1).)
To see why standard blind trials might be suboptimal, consider a design in which partici-
pants are treated with probability p, say p = 0.5. The treatment effect estimated by this blind
trial is
Y1;50%  Y0;50% ¼ ET þ bðp¼0:5Þ  EI:
If there are interaction effects between treatment and behavior (that is, EI 6¼ 0), and if 1/1 odds
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of treatment are not sufﬁcient for participants to engage in large behavioral changes (that is, b
(50%) 0.5), this blind trial does not fully account for the antidepressant’s value added.
Moreover, standard blind trials do not separately identify ET and EI, which matters for fu-
ture experimental and treatment decisions. Large interaction effects between treatment and be-
havior warrants further research to understand precisely what changes in behavior matter for
outcomes. This will also be important information to convey to both physicians
and participants.
This issue can be overcome by implementing a two-by-two factorialized design, where the
first factor is the presence or absence of treatment, and the second is the treatment probability
and the corresponding behavioral response. The insight here is that by randomizing the proba-
bility with which participants are treated, one obtains exogenous variation in behavior patterns
[2, 3]. Two-by-two blind trials proceed in two stages:
1. participants are randomly allocated to two arms: a blind trial with a high probability pH of
being treated, and a blind trial with low probability pL of being treated;
2. participants are informed of their probability of being treated and the blind trials are run in
the usual way.
This is illustrated in Fig 1, which shows the two stages of randomization, with participants first
allocated to either a high- or low-probability treatment group, then informed of this probability
(thus generating the corresponding placebo effect), and then receiving either treatment or non-
treatment in a standard, blinded manner.
The experimenter should make probabilities pL and pH sufficiently different that they can
realistically induce different behavior patterns. Varying the probability of treatment allows the
separate identification of treatment, behavior, and interaction effects as follows:
• T^  E½Y1;pL  Y0;pL  is the pure effect of treatment under the default distribution of behavior
given low probability of treatment;
• B^  E½Y0;pH  Y0;pL  is the pure effect of change in behavior due to greater anticipation of
treatment, conditional on no treatment;
• I^  E½Y1;pH  Y0;pH   E½Y1;pL  Y0;pL  is the interaction effect between treatment and
changes in behavior, that is, the differential effect of getting treatment between participants in
the low probability of treatment and participants in the high probability of treatment groups.
In the previous example, assuming that b(pL)’ 0 and b(pH)’ 1, we fully identify the under-
lying parameters of interest: T^ ¼ ET , B^ ¼ EB and I^ ¼ EI . More importantly, the interpretation
Fig 1. A Two-by-Two Blind Trial.
doi:10.1371/journal.pone.0127227.g001
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of estimators T^ , B^ and I^ as treatment, behavior, and interaction effects, does not rely on the
idealized setting of our example, but holds in all generality. For instance, we can allow for arbi-
trarily complex and random behavioral patterns, as well as heterogeneity in participants’ be-
havior, beliefs, and treatment effects. Note that this generality allows for applications to open
trials and trials using incentives, which is especially useful to research in economic develop-
ment, public health, education, and criminology (see Technical Appendix 1 and [8]). More-
over, the possibility that EB< 0 allows for the possibility of nocebo effects, and for studying
their interaction with treatment.
Data
To look for empirical evidence of interactions between treatment and behavior, we conducted
a meta-analysis of antidepressant trials. Here, our approach is predicated on the two-by-two
design above, in which randomization occurs twice: when assigning participants to the high-
or low-probability treatment arms, and when assigning participants to the treatment or control
group. This ensures that all subpopulations are comparable. While such trials have yet to be
run, we can still implement estimators T^ , B^, and I^ by using multiple trials of the same drug for
which there is significant variation in the participants’ probability of treatment. As all meta-
analyses suffer from possible confounds—different participant populations may differ in unob-
served ways—our results should be interpreted as only suggestive evidence of the utility of two-
by-two trials. Actual trials are needed for a more definitive answer.
We use data originally collected in Fournier et al., which exhaustively searched for all simi-
lar, placebo-controlled blind trials of antidepressants where participant-level data is available
[9] (see Technical Appendix 2). This data is particularly appropriate for our purpose, as behav-
ioral changes during treatment are thought to be important for depression, but complementari-
ties between behavioral changes and treatment are not well understood. Moreover, as this was
the only data we tried to obtain, and the fact that it was collected by outside authors, should re-
duce concerns about multiple-hypothesis testing.
Of the six trials of interest, three are of the selective serotonin re-uptake inhibitor (SSRI)
paroxetine, and three are of the tricyclic antidepressant (TC) imipramine. The treatment prob-
abilities in the SSRI trials are p = 50%, p = 65%, and p = 67%, and the treatment probabilities in
the TC experiments are p = 50%, p = 50%, and p = 70% (see Technical Appendix 2 for addition-
al details). All six trials use the Hamilton Depression Rating Scale (HDRS), which ranges from
0 to 40, with greater scores indicating more severe depression. Our health impact of interest
Yτ,p is the reduction in HDRS over the trial period. This data fits in the two-by-two trial frame-
work by setting pL = 50%, and pH to encompass 65–70%. Note that the U.S. Food and Drug Ad-
ministration (FDA), and human subject review committees, require the disclosure of the
probability of treatment to all participants.
Results
We first looked for evidence that participants behave in a systematically different manner
when they are treated with high probability and when they are treated with low probability.
While the full range of behaviors that participants engage in is not observable, all six trials re-
port whether a participant dropped out of the experiment. For more on how to model dropout
rates and their importance for inference, see [10, 11, 12, 13].
Fig 2, panel (A) shows the dropout rates, with 95% confidence intervals, in the pL and pH tri-
als. It is clear that the dropout rate is significantly lower in the pH trials (p-value< 0.001). This
evidence is reassuring given that the difference between pH and pL is moderate (pH corresponds
to 2/1 odds of treatment, versus 1/1 odds for pL).
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Moreover, as shown in Fig 2, panel (B), this is true trial-by-trial. This leads to a simple statis-
tical test. We test the alternative hypothesis that higher probabilities of treatment are associated
with lower dropout rates against the null that different populations have random dropout
rates, independent of treatment probabilities, and these dropout rates can be greater or less
than the median dropout rate, which is equal to 18.4%. To be maximally conservative, in the
null hypothesis suppose that the probability that any given population has a high or low drop-
out rate is 50%. Under the null hypothesis, the probability that all three low probability of treat-
ment trials have a high dropout rate and all three high probability of treatment trials have a
low dropout rate is 1
64
< 0:02. That is, we can reject the null with p-value< 0.02.
Fig 2, panels (C) and (D) show that this difference in dropout rates between trials is not due
to the treatment—that is, it is not due to the fact that people who are treated drop out with
lower probability. In particular, in both sets of trials, and in each trial individually, there is not
a statistically significant difference in the dropout rates between the treatment and control
group. Indeed, in three out of the six trials the dropout rate is higher (although not statistically
so) among those who are treated than among those in the control group.
Fig 2. Dropout rates are significantly higher in low-probability trials. (A) and (B) show the dropout rate for low versus high treatment probability trials,
and for all six individual trials, respectively. (C) and (D) show the difference in the dropout rate when comparing participants who were treated versus those
that received no treatment. All graphs show point estimates (dots) and 95% confidence intervals centered at the point estimate.
doi:10.1371/journal.pone.0127227.g002
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We next probe the specific influence of behavior on impacts (the change in the HDRS
score). Fig 3 reports estimates and 95% confidence intervals for T^ , B^, and I^ . The analysis shows
that both types of drugs induce large, statistically-significant behavioral effects, but that these
behavioral effects are conceptually very different. In the case of the SSRI paroxetine, there is no
pure effect of behavior or pure effect of treatment, but there is a strong, statistically significant,
decrease in depression due to an interaction between treatment and behavior (I^ ¼ 3:41, s.e. =
1.56, p-value< 0.03 two-tailed). Participants who are more confident that they are being treat-
ed change their behavior in a way that makes the drug more effective, although we do not
know what behaviors are changing. This positive interaction effect cannot be obtained without
the treatment and therefore should be assigned to the value added of the drug. Moreover, the
existence of this interaction effect shows that further research aimed at understanding which
behaviors lead to this effect is warranted. Note that without this interaction, Paroxetine appears
to have no value added.
In contrast, the TC imipramine has a pure treatment effect, a pure effect of behavior
(B^ ¼ 5:09, s.e. = 1.32, p-value< 0.01 two-tailed), but no interaction effect between treatment
and behavior. The effect of behavior alone should not be attributed to the drug. The positive
behavioral effect of the TC imipramine indicates that there is a placebo effect in those studies,
and that none of the studies of either drug shows evidence of a nocebo effect. However, two-
by-two trials may uncover nocebo effects with other treatments.
Fig 3. Behavior matters for both the SSRI and TC, but in different ways. The panels show the effect size (change in HDRS score) as point estimates
(dots) and 95% confidence intervals centered at the point estimate constructed from hetero-skedastic consistent standard errors [14].
doi:10.1371/journal.pone.0127227.g003
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Discussion
In conclusion, we show that, both in theory and on the basis of available data, standard blind
trials can fail to account for the full value added of a treatment when there are interaction ef-
fects between treatment and behavior. We propose the use of two-by-two blind trials, which
randomize both treatment and behavior by varying the probability of treatment across differ-
ent participants. This allows for separate identification of the effects of treatment, behavior,
and their interaction.
There is ample scope for the existence of the interactions identified by two-by-two trials
across a range of medical interventions. The potential for such interactions is determined by
the nature of the placebo effect in specific conditions. Here we have highlighted behavioral
changes, whereby a patient’s optimistic belief in the therapeutic benefit of a treatment may
translate into a potentially observable change in their daily activity. However, placebo effects
can also occur through physiological effects, the nature which is becoming increasingly well
understood across a range of conditions [15]. For example, in chronic pain, placebo effects in-
volve activation of endogenous analgesic (opioidergic) mechanisms [16]. In Parkinson’s dis-
ease, they involve activation of the dopamine system [17]. In both cases, placebos affect the
molecular mechanisms targeted by pharmacological agents. There is also a growing body of ev-
idence pointing to neurally-induced placebo-dependent modulation of inflammatory re-
sponses, likely to be clinically relevant for conditions such as psoriasis and asthma, as well as
other immunological conditions [18]. Similar physiologically-mediated placebo effects are
present in ulcer medicines (H2 blockers and PPIs) and cholesterol lowering medicines (statins)
[2]. In all these cases, two-by-two trials can help evaluate plausible interaction effects between
treatment and the patient’s physiological response to anticipation of treatment.
In addition, in a number of these domains, especially depression and pain, recent research
has identified nocebo effects [19, 20]. These effects are often associated with clinician com-
ments that emphasize the side-effects of treatments [21]. This suggests that our techniques
could be applied to understanding the nocebo effect by randomizing the information to clini-
cians about treatment probability of patients (other work of ours develops the theory behind
this suggestion further [8]). However, it also emphasizes that when employing the two-by-two
trials here, it is important to blind clinicians not just to patients’ treatment status, but also to
patients’ probability of treatment, lest they discuss side-effects more thoroughly with those
with a higher probability of treatment.
Our methodology could be applied to any experiment in which a placebo is administered.
While placebos are rare in evaluations outside of medicine, recent work with agricultural tech-
nologies in development economics shows this may be possible in a larger range of studies
than previously thought [22]. Indeed, using our framework, this work finds significant placebo
effects in evaluating new seed varieties. This suggests that our method could be fruitfully ap-
plied in field experiments in economics and public health to surmount some of the issues in-
trinsic to a standard randomized controlled trials in field settings [23].
We also note that interaction effects could be negative. In this case, standard blinded con-
trolled trials might fail to identify potentially harmful interactions between behavioral or place-
bo effects and an intervention [24]. This could be through either the intended mechanism of
the intervention, or an unwanted side-effect. Either way, our analysis raises a new mechanism
by which positive trial data might not only fail to translate into real-world efficacy, but could
mask deleterious effects.
It is important to note that our evidence relies on a meta-analysis of existing trials in which
probability of treatment is not properly randomized. Hence our results can only be interpreted
as suggestive, and proper two-by-two trials are needed to validate our results. Note, however,
Accounting for Behavior in Treatment Effects
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that the data from two-by-two trial designs can be used to identify the main effects of a treat-
ment at little additional cost in power, even though the specific identification of interactions
may itself require more participants. In other words, two-by-two designs are not any less pow-
erful than standard designs as regards the identification of conventional differences between
treatment and placebo, and will provide more accurate estimates of a treatment’s value added if
significant interaction effects exist ([8] includes more discussion of sample sizes and power).
Notwithstanding our contention that new trials should follow a two-by-two design when
behavioral and placebo effects are thought to be important, we also contend that, where possi-
ble, interaction effects should be incorporated into meta-analyses of existing trial data. Our re-
sults show that this can lead to different conclusions than when interaction effects are
not considered.
Technical Appendices
Technical Appendix 1 provide a formal, general interpretation of estimators T^ , B^, and I^ . Tech-
nical Appendix 2 address a potential confound in our empirical analysis.
Technical Appendix 1 A General Model and Derivation of T^ , B^, and I^
We now provide the general model underlying the interpretation of estimators T^ , B^ and I^ .
This model allows for arbitrary heterogeneity among participants, described by participant-
specific types θ 2Θ Rn0, that summarize all observed and unobserved factors affecting a par-
ticipant’s outcomes. This includes individual traits relevant for therapeutic effects, but also be-
havioral traits affecting a participant’s propensity to engage in various behaviors. Behavior is
described by a vector b 2 B Rn. Altogether a participant’s behavior bθ(p) will depend both on
type θ and probability of treatment p. In all generality, outcomes for a participant of type θ can
be written as
Yt;p;y ¼ myðt; byðpÞÞ þ εt;y;p; ð2Þ
where μθ(τ, bθ(p)) is the expected outcome for participants of type θ under treatment status τ
and behavior bθ(p). The error term ετ, θ, p represents differences in outcomes due to other un-
observed factors, and has expectation E[ετ, θ, pjθ] = 0.
Consider treatment probabilities pL and pH such that 0< pL< pH< 1, this requirement
being necessary for Eq (1) to be estimatable. Estimators T^ , B^ and I^ can be written as
T^ ¼ Ey½myð1; byðpLÞÞ  myð0; byðpLÞÞ;
B^ ¼ Ey½myð0; byðpHÞÞ  myð0; byðpLÞÞ;
I^ ¼ Ey½myð1; byðpHÞÞ  myð0; byðpLÞÞ  T^  B^;
where randomization of both probability of treatment p and treatment status τ ensures that all
expectations are taken over the same distribution of types θ. Hence, for τ 2 {0,1} and p 2 {pL,
pH}, outcomes Yτ, p can be expressed as
Yt;p ¼ E½Y0;pL  þ t T^ þ 1p¼pH  B^ þ t 1p¼pH  I^ þ UY ð3Þ
where E[UYjp, τ] = 0 because τ and p are randomly assigned. Eq (3) generalizes Eq (1), and for-
malizes that T^ , B^, and I^ respectively capture the effect of treatment alone, the effect of change
in behavior alone, and on effects between treatment and behavior when estimated by OLS.
However, note here that behavior refers now to the distribution of behaviors among
the participants.
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This framework allows us to relate our contribution to that of Malani [2] and Malani and
Houser [3]. These papers use similar variation in probability of treatment to identify placebo
effects, and also advocate for incorporating variation in treatment probabilities into random-
ized trials, but do not address complementarities between treatment and behavior. In particu-
lar, in the language of this paper, the data collected by Malani [2] shows that I^ þ B^ > 0 for
ulcer medicines (H2 blockers and PPIs) and cholesterol lowering medicines (statins). However,
as the high-probability trials examined in that paper have a probability 1 of treatment (pH = 1),
it cannot separately identify I^ and B^, which is key to evaluate the value added of a treatment.
Note that this speaks to a more general issue: what should be done when treatment proba-
bilities in a meta-analysis cannot cleanly be divided into high (pH) and low (pL)? In this case,
the term 1p = pH in Eq (3) can be replaced by b(p), where this is a monotonic function of the
probability of treatment. While the specific form of that function should depend on the ana-
lyst’s prior about the shape of the response curve of the placebo or nocebo effect to the proba-
bility of treatment, it likely makes sense to begin the analysis with a linear function.
Technical Appendix 2 A Potential Confound
In any meta-analysis, the fact that the participant populations in different trials may not be
similar can confound the analysis (the two-by-two blind trials described in the paper would re-
solve this issue by randomizing both probability of treatment and treatment status). To allevi-
ate these concerns, we provide more details about the trials analyzed in our empirical work,
and investigate initial severity of depression as a potential confound. Details of the underlying
trials are presented in Table 1, which is a reproduction of Table 1 in Fournier et al. [9], with the
addition of a line indicating the intended probability of treatment in each trial. The original
table also contained extensive information explaining decisions to include or exclude addition-
al data from the analysis. In all cases we have followed exactly the same protocols. The interest-
ed reader can also refer to Fig 1 and surrounding text in Fournier et al. [9] for a complete
description of those authors’ search search and excluding criteria.
There are a few differences in the table that are worth exploring. The first is that three of the
studies use a modified-intent-to-treat analysis, and thus may be dropping a large quantity of
data which could affect the results. A closer look at these studies ameliorates this concern
somewhat. The Dimidijan et al. study drops some data in a way that is orthogonal to assigned
treatment status, and does so before any treatment has been administered. This cannot affect
the results. The Elkin et al. study uses a modified-intent-to-treat design in the paper, but the
data we have available to us contains all participants, so we conduct a full-intent-to-treat analy-
sis. Finally, the Philipp et al. study drops less than 5% of the participants (12 of 263), although
it is unclear whether the decision to drop data is related to treatment status. This is unlikely to
affect results, although it is impossible to say with certainty. This brings up another important
point about the Phillip et al. study: while the probability of being treated with Imipramine in
that study (versus the placebo) is 70%, the experiment also included an arm that was treated
withHypericum extract, which proved to be just as effective as Imipramine. The probability of
receiving any treatment (versus the placebo) was thus 85%. We use 70% in the analysis for con-
sistency with Fournier et al., but the higher 85% probability of treatment would not change
any of our results, and may explain the particularly low dropout rate in this study as shown
in Fig 2.
Second, it is worth noting that although the trials are done across a wide range of time
(1989, 1999, and 2008 for imipramine and 2001, 2005, and 2006 for paroxetine), they were all
conducted when the treatments in question were well-established: the first study of imipramine
was in 1958, and paroxetine was first marketed in 1992.
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Finally, an important difference across the trials reported in Table 1, which can be addressed
statistically, is that the low-probability-of-treatment paroxetine trial also had a participant pop-
ulation with lower initial HDRS scores. this is a potentially important confound, as more severe
initial depression has been associated with larger effects of antidepressant treatment [9]. We at-
tempt to control for initial severity by using a regression framework that includes both proba-
bility of treatment and initial severity as explanatory variables. Table 2 reports the results.
Table 2 replicates our previous empirical results in the first and fourth column, and includes
controls for the initial severity of depression for each participant in the second, third, fifth and
sixth columns. Following [9], we examine two cutoffs for severe depression: an initial
HDRS 25 and an initial HDRS 27. Regardless of the cutoff, the results are qualitatively un-
changed across different specifications.
For the SSRI paroxetine, the interaction effect I^ maintains significance at traditional levels,
but the coefficient attenuates slightly (I^ ¼ 3:01, s.e. = 1.59, p-value< 0.06 two tailed when
using an initial HDRS 25, and I^ ¼ 3:10, s.e. = 1.58, p-value< 0.05 two tailed when using an
initial HDRS 27). The results for the TC imipramine are virtually unchanged by the
Table 1. Details of 6 Studies of Medication and Placebo for Depressed Outparticipants (Table 1 of Fournier et al., 2010).
Trial: Barrett et al. DeRubeis et al. Dimidijan et al. Elkin et al. Philipp et al. Wichers et al.
Probability of treatment 50% 67% 65% 50% 70% 50%
Disorder Minora MDD MDD MDD MDD MDD
No. of intake evaluationsb 1 2 1 2 1 2
No. of treatment sites 2 2 1 3 18 8
Medication Paroxetine Paroxetine Paroxetine Imipramine Imipraminec Imipramine
Target dose, mg/d 20–40 50 50 150–250 100 100–200
Blinded Evaluationsd Yes Yes Partial Yes Partial Partial
HDRS version 17-item Modiﬁed 17-item Modiﬁed 17-item Modiﬁed 17-item 17-item 17-item
Minimum intake severitye 10 20 14 14 18 18
Sample Analyzedf F–ITT F–ITT M–ITT M–ITT M–ITT Complied with protocol
Treatment Duration, wks.g 11 8 8 8 8 6
Abbreviations: F–ITT, full intent to treat; HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; Minor, minor depressive disorder;
M–ITT, modiﬁed intent to treat.
aThe Barrett et al. [25] trial also included participants diagnosed with dysthymia. These participants were not included in the current analysis.
bThe Elkin et al. [26], DeRubeis et al. [27], and Wichers et al. [28] trials required participants to meet inclusion criteria in each of 2 consecutive evaluations
that were held at least 1 week apart.
cThe Philipp et al. [29] trial also included a Hypericum extract condition. Data from this condition were not included in the current analyses.
d
“Yes” indicates that independent blind evaluators conducted evaluations of symptom severity at every assessment. “Partial” indicates that evaluations
were conducted at each session by the treating pharmacotherapists. Treating phamacotherapists were blind to treatment condition.
eSix participants from the Elkin et al. [26] sample registered scores less than 14 on the HDRS at intake (2 from the imipramine and 4 from the placebo
conditions) and 1 participant from the DeRubeis et al. [27] trial registered a score less than 20 (in the paroxetine condition). These participants were
retained in the present analyses.
fThe Barrett et al. [25] and DeRubeis et al. [27] studies used a full intent-to-treat design whereby all participants randomized to treatment were included in
the analysis. The Dimidjian et al. [30], Elkin et al. [26], and Philipp et al. [29] studies used a modiﬁed intent-to-treat approach whereby data from only those
participants who attended at least 1 treatment session or who had 1 postbaseline score were included. The Wichers et al. [28] trial included only those
participants who met minimum compliance requirements for a protocol from a related research question (this sample did include treatment dropouts).
gTreatment in the Elkin et al. [26] trial was provided for 16 weeks. Because target doses were reached by the 8-week assessment, only data through week
8 were analyzed to improve comparability between the studies.
doi:10.1371/journal.pone.0127227.t001
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inclusion of controls for severe depression. This is not surprising as the three TC trials them-
selves, and the participants therein, are very similar.
As a further robustness check we produce results for dropout rates similar to those of Fig 2.
To control for treatment status explicitly, we model the process of dropping out as
Dt;p ¼ b0 þ b1  tþ b2  1p¼pH þ UD; ð4Þ
where 1p = pH takes a value of one if p = pH, and zero otherwise. The parameter of interest here
is β2, which corresponds to the change in dropout rates for high probability of treatment trials.
The first and third columns of Table 3 show the same result as in Fig 2. A higher probability
of treatment is associated with a statistically significant decrease in the probability of dropping
out of the trial (β2 = −0.16, s.e. = 0.056, p-value< 0.01 two tailed). In contrast, treatment status
itself is statistically unrelated to the decision to dropout. The second, third, fifth and sixth col-
umns show that there is no qualitative effect of including controls for initial severe depression.
In summary, our empirical findings are robust to controls for initial severity of depression.
However, it is important to note that the very fact that the probability of treatment varies at a
Table 2. Controlling for the effects of initial severity of depression in anti-depressant trials.
Dependent Variable HDRS reduction (Yτ, p)
Paroxetine (SSRI) Imipramine (TC)
Treatment: T^ -1.32 (1.32) -1.32 (1.33) -1.32 (1.33) 2.94 (1.16) 1.97 (1.11) 1.73 (1.10)
High Probability of Treatment: B^ -0.98 (1.13) -1.58 (1.17) -1.29 (1.16) 5.09 (1.32) 5.45 (1.28) 5.17 (1.30)
High Probability × Treatment: I^ 3.41 (1.56) 3.01 (1.59) 3.10 (1.58) -0.91 (1.74) -0.90 (1.64) -0.77 (1.66)
Severe Depression (Initial HDRS  25) 2.30 (1.52) 4.48 (1.66)
Severe Depression × Treatment 1.84 (2.08) 3.03 (2.13)
Severe Depression (Initial HDRS  27) 2.94 (1.72) 2.67 (2.96)
Severe Depression × Treatment 3.31 (2.67) 6.00 (3.42)
Constant 7.72 (.95) 7.72 (.95) 7.72 (.95) 7.04 (.76) 5.99 (.74) 6.79 (.74)
N 384 384 384 334 334 334
Notes: Speciﬁcations estimated using OLS with hetero-skedastic consistent standard errors in parenthesis [14].
doi:10.1371/journal.pone.0127227.t002
Table 3. Controlling for the effects of initial severity of depression in anti-depressant trials.
Dependent Variable Dropout (Dτ, p)
Paroxetine (SSRI) Imipramine (TC)
Treatment: β1 0.041 (.039) 0.043 (.039) 0.042 (.039) -0.0073 (.039) -0.0030 (.039) -0.0044 (.039)
High Probability of Treatment: β2 -0.15 (.047) -0.16 (.049) -0.15 (.047) -0.20 (.039) -0.20 (.039) -0.20 (.039)
Severe Depression (Initial HDRS  25) 0.071 (.049) -0.090 (.045)
Severe Depression (Initial HDRS  27) 0.067 (.069) -0.040 (0.57)
Constant β0 0.25 (.046) 0.25 (.046) 0.25 (.046) 0.24 (.032) 0.26 (.033) 0.25 (.032)
N 384 384 384 334 334 334
Notes: Speciﬁcations estimated using OLS with hetero-skedastic consistent standard errors in parenthesis [14].
doi:10.1371/journal.pone.0127227.t003
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level of aggregation higher than the individual can lead to issues with estimating standard er-
rors [31]. Standard fixes for this issue, such as clustering of standard errors, or the inclusion of
random effects, are known to produce incorrect results with a small number of observations
(six, in this case). Indeed, this is the case here: using either of these fixes results in t-statistics in
excess of 10 on the coefficients of interest. Thus, we continue to emphasize that while this evi-
dence is reassuring, it is only suggestive. Proper two-by-two trials are needed to validate
our results.
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